Core Insights - The innovative small molecule analgesic drug YJ2301 developed by Professor Li Fei's team at Nanjing Medical University has successfully transitioned from laboratory to market with a total transaction value of nearly 400 million yuan through a partnership with Jiutian Pharmaceutical [1] - The establishment of the first national university regional technology transfer center in Jiangsu aims to facilitate the commercialization of academic research, having already connected over 50 domestic and international universities and generated a total intended transaction value exceeding 800 million yuan [1][2] Value Discovery - The BioMatch initiative launched in February 2025 aims to actively promote high-potential projects like YJ2301 by facilitating connections between universities and enterprises, moving away from passive approaches to technology transfer [2][4] - The center's proactive model of "active exploration + precise matching" has fostered an innovative atmosphere where universities are encouraged to transfer technologies and companies are willing to engage [2] Value Cultivation - The center provides technical guidance and financial support to help early-stage projects navigate challenges such as target validation and safety research, which are critical for moving from laboratory to industry [3][6] - For the YJ2301 project, the center's concept validation team conducted comprehensive evaluations and provided tailored plans to facilitate technology transfer [3] Value Protection - The center has introduced a "pay after use" model to alleviate concerns regarding intellectual property risks for both universities and enterprises, allowing companies to test technologies without significant upfront investments [7] - This model has led to the collection of over 1,000 patent results from more than 20 universities, with agreed "post-payment" amounts exceeding 100 million yuan, enhancing opportunities for early-stage projects to reach the market [7] Value Realization - The center acts as an intermediary to bridge the gap between academic research and market needs, providing professional support in negotiations and contract management to ensure successful collaborations [8] - The comprehensive service model established by the center encompasses the entire process from original research to large-scale production, significantly enhancing the commercialization of academic innovations in the biopharmaceutical industry [8]

Group 1: Product Matrix and Market Position - The company has established a clear and advantageous external product matrix, with significant exclusive and medical insurance advantages in key varieties. Approved products include: Loxoprofen Sodium Gel Patch, Ketoprofen Gel Patch, Anti-inflammatory Pain Relief Patch, Lidocaine Gel Patch, Strong Waist and Bone Strengthening Patch, and Daiwen Moxibustion Patch [2] - The Ketoprofen Gel Patch is a key exclusive product with significant market competitiveness, while the Daiwen Moxibustion Patch holds both traditional Chinese medicine exclusivity and medical insurance exclusivity, showcasing distinct advantages [2] Group 2: Brand Development Strategies - The company has implemented a series of systematic and innovative measures to enhance brand influence and market recognition, including expanding into retail pharmacies and online platforms [3] - A brand upgrade event was held on December 6, 2025, introducing the "JiuDian Pain Relief Expert" symbol and the slogan "Change to JiuDian for Pain Relief Patches," aimed at addressing consumer pain points and enhancing brand communication and market competitiveness [3] Group 3: Sales and Procurement Expectations - The 11th batch of national centralized procurement results will be executed nationwide starting February 2026, with procurement cycles lasting until December 31, 2028 [3] - The company is optimistic about the market prospects for the Ketoprofen Gel Patch, which was approved for listing in 2023 and successfully entered the national medical insurance directory [3] Group 4: Innovation in Drug Development - The company is undergoing a comprehensive transformation towards innovative drug research and development, utilizing a strategy of multiple R&D centers and various drug forms [4] - Two innovation drug R&D centers are being established in central and Yangtze River Delta regions, leveraging local clinical resources and cost advantages [4] - The company is focusing on various tumor and chronic disease indications, employing small molecule drugs, peptide drugs, PDC, and ADC formats [4] Group 5: New Drug Advantages - The newly introduced small molecule pain relief innovative drug YJ2301 is designed to overcome limitations of existing neurogenic pain medications, such as limited efficacy and significant side effects [4] - Clinical pre-research data for YJ2301 shows superior pain relief effects and the potential to address issues like drowsiness and tolerance, providing a new solution for neurogenic pain management [4]